Thinking the unthinkable
Let’s take a quick look at the insulin market. Even with the advent of biosimilar’s Lilly, Novo Nordisk and Sanofi still dominate the market. While insulin remains the most heavily rebated drug it at the same time has become a commodity. Yes, there are slight differences between the insulin offerings both short and long acting but for all practical purposes they are interchangeable.
Try as they might to develop “newer” versions of existing products the insulin’s available today while not perfect do the job just fine. The insulin game is not so much about who has a . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.